Pharmaceutical

Olanzapine ER by Teva Pharmaceutical Industries for Schizophrenia: Likelihood of Approval

Olanzapine ER is under clinical development by Teva Pharmaceutical Industries and currently in Phase III for Schizophrenia.

Jun 18, 2024 - 04:00
Olanzapine ER is under clinical development by Teva Pharmaceutical Industries and currently in Phase III for Schizophrenia.
Read the original article

Tags:

Previous Article

Omalizumab biosimilar by Teva Pharmaceutical Industries for Chronic Urticaria Or...

Next Article

MAS-825 by Novartis for Coronary Artery Disease (CAD) (Ischemic Heart Disease): ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: The complicated connections between weight loss drugs and mental health

Opinion: The complicated connections between weight los...

Feb 19, 2024

Biostax and Immgenuity to expedite HIV immunotherapies development

Biostax and Immgenuity to expedite HIV immunotherapies ...

Aug 30, 2023

STAT+: Nuance’s mysterious pricing, speedier digital health evidence reviews, and new breakthrough devices

STAT+: Nuance’s mysterious pricing, speedier digital he...

Jun 4, 2023